Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: viral RNA polymerase inhibitors - BioCryst

Drug Profile

Research programme: viral RNA polymerase inhibitors - BioCryst

Alternative Names: BCX-5191; BCX4678; Hepatitis C virus RNA polymerase inhibitors - BioCryst

Latest Information Update: 26 Feb 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioCryst Pharmaceuticals; CNRS; Emory University
  • Developer BioCryst Pharmaceuticals
  • Class Nucleosides; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ebola virus infections; Hepatitis C; West Nile virus infections

Most Recent Events

  • 31 Jan 2013 Discontinued - Preclinical for Hepatitis C in USA (PO)
  • 31 Jan 2013 BioCryst terminates preclinical trial in Hepatitis C virus infection in USA
  • 07 Dec 2012 BioCryst announces the company's strategic restructuring with focus on development of antiviral programmes, including BCX 5191 for HCV and a broad spectrum antiviral BCX 4430
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top